Recurrent stroke affects 9% to 15% of people within 1 year. This European Stroke Organisation
(ESO) guideline provides evidence-based recommendations on pharmacological …

Importance Tenecteplase is being evaluated as an alternative thrombolytic agent for the
treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In …

Intravenous thrombolysis (IVT) represents the only systemic reperfusion therapy able to reverse
neurological deficit in patients with acute ischemic stroke (AIS). Despite its effectiveness …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

BACKGROUND Glial fibrillary acidic protein (GFAP) is a biomarker candidate indicative of
intracerebral hemorrhage (ICH) in patients with symptoms of acute stroke. GFAP is released …

Background and Purpose— The term “minor stroke” is often used; however a consensus
definition is lacking. We explored the relationship of 6 “minor stroke” definitions and outcome …

Background Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa
(FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect …

Background Cervical artery dissection is a major cause of stroke in young people (aged <50
years). Historically, clinicians have preferred using oral anticoagulation with vitamin K …

Objective It is not known whether patients with atrial fibrillation (AF) with ischemic stroke
despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how …

Objective: To assess the relationship between seizure burden on continuous EEG (cEEG)
and functional as well as cognitive outcome 3 months after subarachnoid hemorrhage (SAH). …